Skip to main content
. Author manuscript; available in PMC: 2016 Dec 15.
Published in final edited form as: Cancer Res. 2016 Apr 13;76(12):3520–3530. doi: 10.1158/0008-5472.CAN-15-3465

Figure 5. MYC knockdown potentiates TGFβ-induced upregulation of integrin αvβ3 through a SRC-dependent mechanism.

Figure 5

(A) A schematic of the proposed model of signaling. (B–C) TGFβ/MYC KD potentiated PAI-1 expression is blocked by ITGAV KD (B) or SRC KD (C) in MCF10A cells. Transcriptional results are presented as relative quantification, normalized to GAPDH (C,D) SRC knockdown (D) or treatment with SRC kinase inhibitor Dasatinib (E), inhibit MYC knockdown-induced potentiation of TGFβ-induced increase in integrin αvβ3 in MCF10A cells. (F) Dasatinib inhibits MYC knockdown-induced potentiation of TGFβ-induced invasion in MCF10A cells. Error bars, SEM; * p<0.5; ** p<0.01; *** p<0.001.